A phase 2 study for intermediate risk neuroblastoma based on IDRF (Image Defined Risk Factors)

Phase 2

• Conditions: neuroblastoma; intermediate; D009447

• Registration Number: JPRN-jRCTs051180203
• Lead Sponsor: iehara tomoko

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-03-27
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 75

Inclusion Criteria

Patients with INSS stage 3 without MYCN amplification, who include children over12 months with favorable histology and 12 to 18 months with unfavorable histology.
Patients with INSS stage 4 without MYCN amplification, who include children under 12 months and 12 to 18 months with favorable histology and DNAindex>1
Patients with INSS stage 4s without MYCN amplification, who include children under 12 months with unfavolable histology or favorable histology and DNAindex=1

Exclusion Criteria

(1) duplicated cancer cases. (2) A pregnant woman or a woman who may be pregnant or a lactating woman. (3) cases are merging psychoses or psychiatric symptoms. (4) cases who considers a disease, severe complication, or severe malformation that a doctor deems inappropriate to participate in this study. (5) cases of respiratory failure requiring intubation, cases with coagulopathy presenting DIC and the like

Study & Design

• Study Type: Interventional
• Study Design: Not specified